FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Maintains Buy Rating On Shares Of Iqvia

By

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We keep our 12-month price target at $210, based on 16.4x our 2026 EPS estimate, above IQV's one-year historical forward average of 15.6x but a discount to its five-year historical forward average of 20.6x. This is justified by recent headwinds for key life sciences end markets due to macroeconomic pressures, uncertain tariff and research funding policy, and weaker biotech spending and clinical trial activity, in our view. We raise our 2026 EPS estimate to $12.80 from $12.70 and lower our 2027 estimate by $0.07 to $14.12. Adjusted for IQV's new segment reporting, R&DS saw net new bookings of $2.5B in Q1 2026 (up 3.6% Y/Y), generating a book-to-bill ratio of 1.04x, somewhat weaker than recent trends. Management attributed this to an unfavorable clinical trial mix rather than an indicator of weakening demand. Per Q1 earnings commentary, the company has deployed 192 AI agents across 64 use cases, with 19 of the top-20 pharmaceutical companies having adopted some of these offerings.

Related Articles

Research

Research Alert: Grab Achieves $120m Q1 Profit With 24% Revenue Growth, Reaffirms Guidance

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Grab posted strong Q1 2026 results with revenue of $955M (+24% Y/Y) and net profit of $120M vs. $10M in the prior year, marking the second consecutive quarter of GAAP profitability. Adjusted EBITDA surged 46% Y/Y to $154M, with margin expanding 250 bps to 16.2%, demonstrating operating leverage in all segments including Mobility GMV growth of 23% and Deliveries GMV expansion of 25%. Key strategic milestones include securing Singapore's inaugural cross-border ride-hail license for the Singapore-Johor corridor and announcing its first international expansion through the acquisition of Taiwan's foodpanda. Executing $500M in share repurchases reflects management's confidence. Management maintained full-year 2026 revenue guidance of $4.04B-$4.10B and $700M-$720M in Adjusted EBITDA, which in our view, indicates confidence in sustained momentum. Financial Services revenue grew 43% to $107M with loan portfolio more than doubling to $1.4B, while strong advertising monetization led Deliveries profitability improvements.

$GRAB
Research

Research Alert: CFRA Maintains Hold Opinion On Shares Of Alliant Energy Corporation

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target by $2 to $75, valuing LNT at 21.5x our next-12-month EPS view. We trim our 2026 EPS view by $0.03 to $3.42 and trim 2027 by $0.02 to $3.68. Rate base growth stemmed from investments in generation, energy storage, and transmission assets, along with higher allowance for funds used during construction. LNT signed an additional ~370 MW electric service agreement in Iowa, bringing total contracted data center demand to ~3.4 GW (up from 3 GW previously), with the potential to add another 2-4 GW depending on ongoing negotiations. LNT now has five fully executed data center agreements, with three projects under active construction. In our opinion, the strategic focus on capacity-only electric service agreements, supported by flexible generation (simple cycle natural gas and battery storage), aligns capital deployment with revenue growth while preserving optionality for future energy needs. We think EPS and dividend growth (2025-2028) is attractive at 7.6% and 6.1%, respectively.

$LNT
Research

Research Alert: CFRA Maintains Hold Opinion On Shares Of Builders Firstsource, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target to $85 from $125, based on a 2027 P/E of 13.1x, a premium to the stock's 10-year average forward P/E of 12.1x, justified by cyclical trough market conditions. We lower our adjusted EPS estimates to $4.10 from $6.69 for 2026 and to $6.50 from $8.01 for 2027. BLDR posted Q1 2026 adjusted EPS of $0.27 vs. $1.51 (-82% Y/Y), well short of the $0.37 consensus. BLDR's Q1 sales fell 11% to $3.29B ($130M ahead of consensus), but gross margin contracted 220 bps to 28.3%. BLDR said it now expects 2026 net sales of $14.6B-$15.6B and adjusted EBITDA of $1.1B-$1.5B, versus prior expectations of $14.8B-$15.8B and $1.3B-$1.7B, respectively. Management said it remains focused on factors within its control, including serving customers, expanding its differentiated portfolio of value-added solutions, and leveraging technology to accelerate growth and drive operational excellence. We think BLDR's Q1 results underscore challenges the company faces from a weaker housing market.

$BLDR